Auto-Injectors Market size valued 45.4 billion in 2020 and expected to reach USD 109.5 billion by 2027, at a CAGR of 17.6% during the forecast period 2021-2027. Auto-Injector is a medical device that is used to self-inject doses of drugs, typically life-saving drugs. Auto-injector keeps the needle tip covered before injecting and also has a safety mechanism to prevent accidental injection. auto-injector market are gaining importance these days to manage the severe conditions like anaphylaxis, rheumatoid arthritis, multiple sclerosis, and others. Most of the auto-injectors are single-dose and spring-loaded syringes. The site of injection depends upon the drug loaded. Auto-Injectors are easy to use and intended for self-administration by patients or any other caretaker or personnel at home. auto injector market manufacturers are diversifying the product portfolio by introducing low-cost auto injector products, incorporate advanced features into products, and with new product launches. For instance, Mylan N.V. introduced a generic version of epipen by reducing the price to half of its original product price. The initial pack of two was sold at US$ 600 until December 2016 that will be sold at US$ 300 from January 2017. Bayer AG introduced betaconnect, an electronic auto injector to treat relapsing-remitting multiple sclerosis in 2016. Companies are actively involved in collaborations and taking license agreements for auto-injector technology. In September 2016, Aptar Pharma (AptarGroup, Inc.) collaborated with Becton, Dickinson and Company (BD) to develop an auto injector using prefillable syringes from BD and Aptar Pharma’s two-step auto-injector technology.